While the inner workings of and interactions between the various healthcare industry branches are extremely complex, demand for its products and services is not likely to wane. In an article for this week’s TheStreet, Validea CEO John Reese offers his perspective on industry prospects and identifies four stock picks with good vital signs: Johnson & Johnson (JNJ) is engaged in the research and development, manufacture and sale of a range of products in the health care field. It earns solid scores under our guru strategies based in part on healthy cash flow per share and trailing 12-month sales of more […]
Many biotech stocks have had exceptional runs over the past few years. But newsletter guru Jim Oberweis says that has led to some exorbitant valuations, and he says there are other ways to now play the healthcare sector.
The healthcare sector has been enjoying a good 2014 despite some big headwinds, and in an interview with Fox Business Network, Validea CEO John Reese looks at how his Guru Strategies have been taking advantage of that.
While many investors are afraid of healthcare stocks right now because of the possibility of major industry reforms, the lone diversified stock fund manager to make money in 2008 is bullish on the sector. Tom Forester of the Forester Value fund says he thinks much of the potential bad news is already priced into healthcare stocks, Fortune reports. And with the sector trading at about seven times earnings vs. around 20 for the broader market, he’s staying with it. “These are emotionally difficult stocks to hold right now because they are in the crosshairs,” he says. “[But] value guys are […]